Hims & Hers Health, Inc. (HIMS) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Hims & Hers Health, Inc. Do?
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California. Hims & Hers Health, Inc. (HIMS) is classified as a mid-cap stock in the Healthcare sector. The company is led by CEO Andrew Dudum and employs approximately 650 people. With a market capitalization of $4.4B, HIMS is one of the notable companies in the Healthcare sector.
Hims & Hers Health, Inc. (HIMS) Stock Rating — Reduce (April 2026)
As of April 2026, Hims & Hers Health, Inc. receives a Reduce rating with a composite score of 31.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.HIMS ranks #3,671 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Hims & Hers Health, Inc. ranks #587 of 839 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
HIMS Stock Price and 52-Week Range
Hims & Hers Health, Inc. (HIMS) currently trades at $19.14. The 52-week high for HIMS is $70.43, which means the stock is currently trading -72.8% from its annual peak. The 52-week low is $13.74, putting the stock 39.3% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is HIMS Overvalued or Undervalued? — Valuation Analysis
Hims & Hers Health, Inc. (HIMS) carries a value factor score of 50/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 24.66x, compared to the Healthcare sector average of 23.29x — a premium of 6%. The price-to-book ratio stands at 8.36x, versus the sector average of 2.69x. The price-to-sales ratio is 2.12x, compared to 1.64x for the average Healthcare stock. On an enterprise value basis, HIMS trades at 38.07x EV/EBITDA, versus 6.36x for the sector.
Overall, HIMS's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Hims & Hers Health, Inc. Profitability — ROE, Margins, and Quality Score
Hims & Hers Health, Inc. (HIMS) earns a quality factor score of 45/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 33.9%, compared to the Healthcare sector average of -42.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 8.5% versus the sector average of -33.1%.
On a margin basis, Hims & Hers Health, Inc. reports gross margins of 75.7%, compared to 71.3% for the sector. The operating margin is 5.6% (sector: -65.2%). Net profit margin stands at 9.4%, versus -54.1% for the average Healthcare stock. Revenue growth is running at 89.8% on a trailing basis, compared to 10.7% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
HIMS Debt, Balance Sheet, and Financial Health
Hims & Hers Health, Inc. has a debt-to-equity ratio of 298.0%, compared to the Healthcare sector average of 31.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.90x, suggesting adequate working capital coverage. Total debt on the balance sheet is $971M. Cash and equivalents stand at $346M.
HIMS has a beta of 1.94, meaning it is more volatile than the broader market — a $10,000 investment in HIMS would be expected to move 93.6% more than the S&P 500 on any given day. The stability factor score for Hims & Hers Health, Inc. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Hims & Hers Health, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Hims & Hers Health, Inc. reported revenue of $2.13B and earnings per share (EPS) of $0.57. Net income for the quarter was $183M. Gross margin was 75.7%. Operating income came in at $119M.
In FY 2025, Hims & Hers Health, Inc. reported revenue of $2.35B and earnings per share (EPS) of $0.57. Net income for the quarter was $128M. Gross margin was 73.8%. Revenue grew 59.0% year-over-year compared to FY 2024. Operating income came in at $106M.
In Q3 2025, Hims & Hers Health, Inc. reported revenue of $599M and earnings per share (EPS) of $0.07. Net income for the quarter was $16M. Gross margin was 73.8%. Revenue grew 49.2% year-over-year compared to Q3 2024. Operating income came in at $12M.
In Q2 2025, Hims & Hers Health, Inc. reported revenue of $545M and earnings per share (EPS) of $0.19. Net income for the quarter was $43M. Gross margin was 76.4%. Revenue grew 72.6% year-over-year compared to Q2 2024. Operating income came in at $27M.
Over the past 8 quarters, Hims & Hers Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $316M to $2.13B. Investors analyzing HIMS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
HIMS Dividend Yield and Income Analysis
Hims & Hers Health, Inc. (HIMS) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
HIMS Momentum and Technical Analysis Profile
Hims & Hers Health, Inc. (HIMS) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.
HIMS vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Hims & Hers Health, Inc. (HIMS) ranks #587 out of 839 stocks based on the Blank Capital composite score. This places HIMS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.
Comparing HIMS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HIMS vs S&P 500 (SPY) comparison to assess how Hims & Hers Health, Inc. stacks up against the broader market across all factor dimensions.
HIMS Next Earnings Date
No upcoming earnings date has been announced for Hims & Hers Health, Inc. (HIMS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy HIMS? — Investment Thesis Summary
The quantitative profile for Hims & Hers Health, Inc. suggests caution. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 14/100) increases portfolio risk.
In summary, Hims & Hers Health, Inc. (HIMS) earns a Reduce rating with a composite score of 31.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HIMS stock.
Related Resources for HIMS Investors
Explore more research and tools: HIMS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HIMS head-to-head with peers: HIMS vs AZN, HIMS vs SLGL, HIMS vs HOLX.